Anticholinergics for urinary symptoms in multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Nicholas, Richard S ^a   Friede, Tim ^b   Hollis, Sally ^c   Young, Carolyn A ^d  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Cholinergic antagonists adverse effects; *therapeutic use ; Humans; Multiple sclerosis *complications ; Randomized controlled trials as topic; Urinary bladder, overactive *drug therapy; etiology

Indexed keywords

ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLAVOXATE; MELADRAZINE TARTRATE; METHANTHELINE BROMIDE; OXYBUTYNIN; PROPANTHELINE BROMIDE; UNCLASSIFIED DRUG;

BLADDER CAPACITY; BLADDER CONTRACTION; CHOLINERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; COCHRANE LIBRARY; CROSSOVER PROCEDURE; DATA ANALYSIS; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; MULTIPLE SCLEROSIS; NOCTURIA; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY URGENCY;

EID: 70249148902     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004193.pub2     Document Type: Review

References (76)

1. Fader M, Glickman S, Haggar V, Barton R, Brooks R, Malone-Lee J. Intravesical Atropine Compared to Oral Oxybutynin for Neurogenic Detrusor Overactivity: A Double-Blind, Randomized Crossover Trial. Journla of Urology 2007;177:208-213 (Pubitemid 44879451)
2. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. Journal of Urology 1986;135(5):966-968
3. Hebjorn S. Treatment of detrusor hyperreflexia in multiple sclerosis: a double-blind, crossover clinical trial comparingmethantheline bromide (Banthine), flavoxate chloride (Urispas) and meladrazine tartrate (Lisidonil). Urology International 1977;32(2-3):209-217 (Pubitemid 8166144)
4. Atan A, Konety BR, Nangia A, Chancellor MB. Advantages and risks of ileovesicostomy for the management of neuropathic bladder. Urology 1999;54(4):636-640 (Pubitemid 29449422)
5. Bennett N, O'Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder?. Journal of Urology 2004;171(2):749-751 (Pubitemid 38090473)
6. Berghmans B, Bo K, Hendriks E, van Kampen M, de Bie R. Electrical stimulation with non implanted electrodes for urinary incontinence in adults. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD001202.pub2]
7. Burguera-Hernandez JA. Urinary alterations in multiple sclerosis. Revue Neurologique 2000;30:989-992
8. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Archives of Physical Medicine and Rehabilitation 2006;85:536-545
9. Coggrave M, Wiesel PH, Norton C, Brazzelli M. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD002115.pub3%C2%A0%C2%A0]
10. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003;63:153-166 (Pubitemid 36143342)
11. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al.Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scandanavian Journal of Urology and Nephrology 2007;41:335-340 (Pubitemid 47357195)
12. Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers OI. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. Journal of Spinal Cord Medicine 2004;27(3):214-218
13. Faller NA. Oxybutynin dosage questioned. Journal of Enterostomy Nursing 1992;19:190.
14. Fowler CJ, van Kerrebroeck PE, Nordenbo A, Van Poppel H. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). Journal of Neurology Neurosurgery and Psychiatry 1992;55:986-989
15. Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Vespasiani G, Castellano V. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourology and Urodynamics 1998;17(2):89-98. (Pubitemid 28150528)
16. Gomes CM, Trigo-Rocha F, Arap MA, Gabriel AJ, Alaor de Figueiredo J, Arap S. Schistosomal myelopathy: urologic manifestations and urodynamic findings. Urology 2002;59:195-200. (Pubitemid 34134513)
17. Hay Smith J, Herbison P, Ellis G, Moore K. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003781]
18. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Journal of Urology 2006;25:441-445
19. Jameson PM. Management of the bladder in non-traumatic paraplegia. Paraplegia 1974;12:92-97
20. Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004375. pub2]
21. Jensen D. Treatment of detrusor hyperreflexia in sclerosis multiplex. Journal of Oslo City Hospital 1989;39:67-73.
22. Karsenty G, Corcos J, Schurch B, Ruffion A, Chartier-Kastler E. Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections. Progress in Urology 2007;17:568-575
23. Kim JH, Rivas DA, Shenot PJ, Green B, Kennelly M, Erickson JR, et al.Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. Journal of Spinal Cord Medicine 2003;26(4):358-363 (Pubitemid 37549376)
24. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, et al.Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Zeitschrift für Rheumatologie 2000;59 suppl 1:48-52.
25. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. European Urology 2003;44:165-174 (Pubitemid 36916999)
26. O'Flynn KJ, Thomas DG. Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. British Journal of Urology 1993;72:566-570
27. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: A randomized controlled study. Clinical Rehabilitation 2003;17:42-47 (Pubitemid 36230979)
28. Rabey JM, Moriel EZ, Farkas A, Firstater M, Vardi I, Streifler M. Detrusor hyperreflexia in multiple sclerosis. Alleviation by a combination of imipramine and propantheline, a clinico-laboratory study. European Neurology 1979;18:33-37 (Pubitemid 9157753)
29. Ruud Bosch JL, Groen J. Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. Lancet 1996;348:717-719 (Pubitemid 26302307)
30. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. European Urology 2007;52:858-859 (Pubitemid 47126174)
31. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Archives of Physical Medicine and Rehabilitation 2007;88:646-652
32. Schurch B. Botulinum toxin for the management of bladder dysfunction. Drugs 2006;66:1301-1318 (Pubitemid 44246615)
33. Whitaker JN, Kachelhofer RD, Bradley EL, Burgard S, Layton BA, Reder AT, et al.Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Annals of Neurology 1995;38:625-632
34. Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scandanavian Journal of Urology and Nephrology 1988;114(Suppl):5-19. (Pubitemid 19065256)
35. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology 1998;81(6):801-810 (Pubitemid 28300606)
36. Anonymous. Managing incontinence due to detrusor instability. Drugs and Therapeutics Bulletin 2001;39(8):59-64.
37. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al.Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clinic Proceedings 2001;76(4):358-363 (Pubitemid 32248750)
38. Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Managed Care Interface 2000;13(2):88-94.
39. Becker MP, Balagtas CC. Marginal modelling of binary cross-over data. Biometrics 1993;49(4):997-1009.
40. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 1993;56(3):245-250
41. Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current medical research and opinion 2007;23:2347-2358 (Pubitemid 350033436)
42. Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. Urology 2001;57(2):239-245
43. Curtin F, Altman DG, Elburne D.Meta-analysis combining parallel and cross-over clinical trials I: Continuous outcomes. Statistics in Medicine 2002;21:2131-2144. (Pubitemid 34830752)
44. Dasgupta P, Haslam C, Goodwin R, Fowler CJ. The 'Queen Square bladder stimulator': a device for assisting emptying of the neurogenic bladder. British Journal of Urology 1997;80(2):234-237 (Pubitemid 28318888)
45. De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. Journal of Urology 1997;158(6):2087-2092 (Pubitemid 27481333)
46. De Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurologica Belgica 1999;99(1):61-64
47. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-188.
48. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, Murtz G, et al.Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. European Urology 2000;37(6):702-708 (Pubitemid 30255788)
49. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A, et al.Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-149 (Pubitemid 34284916)
50. Eustice S, Roe B, Paterson J. Prompted voiding for the management of urinary incontinence in adults. Cochrane Database of Systematic Reviews 2000;2:CD002113.
51. Gallien P, Robineau S, Nicolas B, Le Bot MP, Brissot R, Verin M. Vesicourethral dysfunction and urodynamic findings inmultiple sclerosis: a study of 149 cases. Archives of Physical Medicine and Rehabilitation 1998;79(3):255-257 (Pubitemid 28207111)
52. Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Finazzi Agro E, Collura G, et al.Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Archives of Physical Medicine and Rehabilitation 1999;80(4):437-441 (Pubitemid 29171959)
53. Gray R, Wagg A, Malone-Lee JG. Differences in detrusor contractile function in women with neuropathic and idiopathic detrusor instability. British Journal of Urology 1997;80(2):222-226 (Pubitemid 28318886)
54. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology 2004;45:420-429.
55. Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. American Journal of Obstetrics and Gynecology 2001;185:56-61. (Pubitemid 32681794)
56. Hay-Smith EJ, Bo K, Berghmans LC, Hendriks HJ, de Bie RA, van Waalwijk V. Pelvic floor muscle training for urinary incontinence in women. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD001407]
57. Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. Journal of Neurology 1999;246(11):1027-1032
58. Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 1998;65(5):778-780 (Pubitemid 28486663)
59. Koldewijn EL, Hommes OR, Lemmens WA, Debruyne FM, van Kerrebroeck PE. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. Journal of Urology 1995;154(1):169-173
60. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-1452
61. Litwiller SE, Frohman EM, Zimmern PE.Multiple sclerosis and the urologist. Journal of Urology 1999;161(3):743-757
62. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al.Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001;50(1):121-127
63. Mori S, Kojima M, Sakai Y, Nakajima K. [Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride]. Nippon Ronen Igakkai Zasshi 1999;36(7):489-494
64. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003781. pub2%C2%A0%C2%A0]
65. Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999;399 Suppl 6738:A40-7.
66. Ouslander JG, Schnelle JF, Uman G, Fingold S, Nigam JG, Tuico E, et al.Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. Journal of the American Geriatrics Society 1995;43(6):610-617
67. Pelman RS, Capo JP Jr, Forero-Schwanhaeuser S. Solifenacin at 3 years: a review of efficacy and safety. Postgraduate Medicine 2008;120:85-91.
68. Porru D, Campus G, Garau A, Sorgia M, Pau AC, Spinici G, et al.Urinary tract dysfunction in multiple sclerosis: is there a relation with disease-related parameters?. Spinal Cord 1997;35(1):33-36 (Pubitemid 27049524)
69. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227-231 (Pubitemid 13158528)
70. Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001308]
71. The National Collaborating Centre for Chronic Conditions at the Royal College of Physicians. Multiple Sclerosis: National clinical guideline for diagnosis and management in primary and secondary care. The Royal College of Physicians. London: The Royal College of Physicians, 2004.
72. Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder. Annals of Pharmacotherapy 1999;33(10):1073-1082 (Pubitemid 29489990)
73. Schumacher GA, Beebe GW, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al.Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Annals of the New York Academy of Science 1965;122:552-568
74. Stohrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord 1999;37(3):196-200. (Pubitemid 29149996)
75. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Archives of Neurology 1996;53(12):1270-1275 (Pubitemid 26425073)
76. Wood S, Coulson R. Adverse drug reactions on-line Information tracking (ADROIT). Pharmaceutical Medicine 1993;7:203-213 (Pubitemid 23336786)